Mentioned briefly above, the gold standard treatment for MS, DMF (Tecfidera), has also been shown to activate NRF2 in MS patient blood and immune cells (Gopal et al., 2017; Hammer et al., 2018; Carlstrom et al., 2019). This evidence concerns the gene NFE2L2 and myeloid sarcoma.